IRIS
CHITI, ARTURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.116
EU - Europa 1.972
AS - Asia 1.014
AF - Africa 349
SA - Sud America 14
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 6
Totale 13.482
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.949
FI - Finlandia 542
SG - Singapore 437
IE - Irlanda 398
NG - Nigeria 348
CN - Cina 283
DE - Germania 226
IT - Italia 186
FR - Francia 163
CA - Canada 161
SE - Svezia 119
NL - Olanda 116
IN - India 107
GB - Regno Unito 84
TR - Turchia 80
IL - Israele 48
BE - Belgio 47
RU - Federazione Russa 36
HK - Hong Kong 26
IR - Iran 13
AT - Austria 10
CZ - Repubblica Ceca 9
CL - Cile 8
EU - Europa 8
BR - Brasile 5
JP - Giappone 5
TW - Taiwan 5
AU - Australia 4
CH - Svizzera 4
ES - Italia 4
PA - Panama 4
UA - Ucraina 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
EE - Estonia 3
RO - Romania 3
TH - Thailandia 3
BD - Bangladesh 2
GR - Grecia 2
HR - Croazia 2
MX - Messico 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PL - Polonia 2
AL - Albania 1
AR - Argentina 1
DK - Danimarca 1
EG - Egitto 1
HU - Ungheria 1
IS - Islanda 1
KR - Corea 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
PT - Portogallo 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 13.482
Salva come PNG Salva come JPEG
Città #
Wilmington 2.010
Chandler 1.882
San Mateo 776
Ann Arbor 609
Helsinki 542
Leawood 401
Dublin 397
Boardman 352
Benin City 348
Lawrence 327
Princeton 327
Singapore 283
Ashburn 279
Shanghai 225
Fairfield 195
New York 184
Woodbridge 181
Paris 160
Toronto 158
Amsterdam 110
Pune 94
Kocaeli 80
London 73
Milan 72
Seattle 59
San Diego 57
Norwalk 49
Brussels 46
Monmouth Junction 44
Beijing 30
Falls Church 30
Santa Clara 29
Moscow 27
Phoenix 20
Houston 16
Los Angeles 16
Redmond 15
Redwood City 14
Cambridge 11
Des Moines 10
Falkenstein 10
Berlin 9
Tappahannock 9
Terracina 8
Vienna 8
Abbiategrasso 7
Andover 7
Brno 7
Florence 7
Munich 7
Zhengzhou 7
Augusta 5
Frankfurt am Main 5
Hanover 5
Jacksonville 5
Chengdu 4
Mumbai 4
Sacramento 4
Samarate 4
San Jose 4
St Petersburg 4
Clearwater 3
Genoa 3
Hangzhou 3
Hebei 3
Mestre 3
Osimo 3
Pozzuoli 3
Rogeno 3
Saint Paul 3
Tallinn 3
Apo 2
Avigliano 2
Bangkok 2
Bari 2
Buffalo 2
Chongqing 2
Guangzhou 2
Gurgaon 2
Hull 2
Issiglio 2
Kaohsiung City 2
Kwun Hang 2
Las Vegas 2
Norfolk 2
Rotterdam 2
Saint Louis 2
Schwenksville 2
Sherbrooke 2
Sovico 2
São Paulo 2
Taipei 2
Trento 2
Umeå 2
Valencia 2
Xalapa 2
Zagreb 2
Alcamo 1
Ardabil 1
Athens 1
Totale 10.753
Salva come PNG Salva come JPEG
Nome #
11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer. 95
111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer. 90
111In-octreotide uptake in granulomatous and tumor lesions in a patient with small-cell lung cancer 85
11Cl-choline PET/CT in imaging locally advanced prostate cancer 79
Applications of PET imaging with radiolabelled choline (C-11/F-18-choline) 75
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 73
Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions 69
arallel comparison of 68Ga-Prostate Specific Membrane Antigen PET-CT and PRIMUS in primary prostate cancer diagnosis 69
A portrait of the scientist as a young woman Comments after the first EANM Young Investigators' Meeting 67
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 67
Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery 66
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 66
Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals 64
A case of metastatic axillary lymph nodes involvement from unknown primary cancer: Clinical usefulness of [Tc-99m]-sestamibi 64
Ga-68-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study 64
Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-68-DOTA-conjugated somatostatin receptor targeting peptides and F-18-DOPA 63
PREDICTIVE VALUE OF EARLY PET DURING SALVAGE CHEMOTHERAPY IN RELAPSING/REFRACTORY HODGKIN'S LYMPHOMA (HL) PATIENTS 63
[F-18] FDG PET/CT features for the molecular characterization of primary breast tumors 63
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy 62
Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail 60
INDIUM-111-DTPA-OCTREOTIDE SCINTIGRAPHY MODULATION BY TREATMENT WITH UNLABELED SOMATOSTATIN ANALOG IN SMALL-CELL LUNG-CANCER 60
C-11-Methionine uptake in secondary brain epilepsy 60
Ga-68-PSMA PET/CT for primary diagnosis of prostate cancer in men with contraindications to or negative mpMRI 60
Prospective evaluation of Ga-68-PSMA PET/CT in primary prostate cancer diagnosis - final results of a dedicated trial 60
68GA-PSMA PET/CT FOR PRIMARY DIAGNOSIS OF PROSTATE CANCER IN MEN WITH CONTRAINDICATIONS TO OR NEGATIVE MRI: A PROSPECTIVE OBSERVATIONAL STUDY 60
I-131/I-123-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging 59
Application of Convolutional Neural Networks is promising in the definition of T-stage in lung cancer 58
A DOUBTFUL IMAGE OF LEVEEN SHUNT PATENCY 58
Radiopharmaceuticals for breast cancer imaging 57
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 57
Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer: Can positron emission tomography (PET) with F-18-FDG be considered as the best method? 56
Baseline FDG-PET/CT Radiomics to Predict Outcome in Lung Cancer Patients Treated with Surgery 56
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 56
Molecular Imaging in Radiotherapy Planning for Head and Neck Tumors 56
Evaluation of response: is F-18-FDG PET the answer? 55
Pancreatic cancer or chronic pancreatitis? An answer from PET/MRI image fusion 55
Value of FDG-PET/CT radiomic features in predicting response to anti-programmed death 1 (PD-1) antibodies treatment in refractory Hodgkin Lymphoma patients 55
Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma 55
Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol 2011;59:572-83 54
The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine 54
PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014 54
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma 54
Texture analysis and machine learning to characterize suspected thyroid nodules and differentiated thyroid cancer: Where do we stand? 53
Convolutional Neural Networks Promising in Lung Cancer T-Parameter Assessment on Baseline FDG-PET/CT 53
Endorsement of International Consensus Radiochemistry Nomenclature Guidelines 53
Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma 53
Multimodal Characterization of Supratentorial Gliomas: Relationship Among Morphological, Metabolic and Molecular features 52
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 52
Clinical implications of immunohistochemical assessment of somatostatin receptors subtype 2 and 5 in the diagnostic and therapeutic management of gastro-entero-pancreatic neuroendocrine tumours 52
Prone scintimammography in patients with non-palpable breast lesions 52
EANM procedure guideline for treatment of refractory metastatic bone pain 51
The Path to the Future: Education of Nuclear Medicine Therapeutic Specialists as Responsible Physicians 51
F-18-DOPA PET/CT in Neuroblastoma Comparison of Conventional Imaging With CT/MR 51
Bone lesion in a patient with transplanted liver for a metastatic carcinoid. The role of somatostatin receptor scintigraphy 51
F-18-FDG PET/CT scans for children and adolescents 51
Baseline Radiomic CT Features Differentiate Mediastinal Masses As Thymic Neoplasms Or Lymphomas 51
A risk management approach for imaging biomarker-driven clinical trials in oncology 51
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 51
Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas 51
C-11-labeled methionine and evaluation of malignant pleural mesothelioma 50
Cardiac and Acoustic Metastases in Relapsing Melanoma 50
The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors | [La scintigrafia dei recettori per la somatostatina nei tumori neuroendocrini gastro-entero-pancreatici.] 50
Standardization and quantification in PET/CT imaging: tracers beyond FDG. 50
Prognostic significance of molecular and imaging biomarkers in primary brain tumors 50
CASE-REPORT - TECHNETIUM-99M-HEXAKIS-2-METHOXY-ISOBUTYL-ISONITRILE IMAGING OF BREAST-CANCER AND MYOCARDIAL-INFARCTION IN THE SAME PATIENT 50
Nuclear medicine procedures in lung cancer 49
Correlation of microvascular fractal dimension with positron emission tomography [C-11]-methionine uptake in glioblastoma multiforme: Preliminary findings 49
A case of atypical giant cell arteritis diagnosed by positron emission tomography (PET) 49
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 49
Positron Emission Tomography-Computed Tomography for Patients with Recurrent Colorectal Liver Metastases: Impact on Restaging and Treatment Planning 49
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 49
FDG PET/CT predictive role in follicular lymphoma 48
Assessment of mediastinal involvement in lung cancer with technetium-99m-sestamibi SPECT 48
Assessment of tumor response in malignant pleural mesothelioma 48
PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology 48
New Clinical Indications for F-18/C-11-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature 48
Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma 48
Pretransplantation pet as major prognostic discriminant in IGEV-treated patients with refractory/relapsed Hodgkin's lymphoma (HL) 48
In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging 47
SEGMENTAL FDG-PET/CT IN SOLITARY PULMONARY NODULE: PRELIMINARY DATA OF THE PET ITALIAN TRIAL 47
Consensus on molecular imaging and theranostics in prostate cancer 47
Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis 47
Fourier amplitude image circumferential profile analysis in the evaluation of the dipyridamole test 47
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome 47
Reply to comment on Pepe et al.: Somatostatin receptor SPECT 46
Introduction to EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD) 46
Exploration of Disease Markers under Translational Medicine Model 46
Diffusion-weighted imaging and loco-regional N staging of patients with colorectal liver metastases 46
Why New Journals? The Growth of the EJNMMI Family 46
Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy 46
Role of I-131-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours - Experience of the National Cancer Institute of Milan 46
Feasibility of Carbidopa Premedication in Pediatric Patients: A Pilot Study 46
SENSITIVITY VERSUS SPECIFICITY IN MELANOMA IMAGING USING I-123 IODOBENZAMIDE AND IN-111 PENTETREOTIDE 46
F-18-FDG-PET (PET) and contrast-enhanced CT-scan (CT) in the evaluation of liver metastases from colorectal cancer after chemotherapy 46
Random forest analysis to predict Disease-Free Survival using FDG-PET and CT in Lung Cancer 46
A method to reduce acetonitrile amount in F-18-FDG synthesis 46
[C-11] Choline PET/CT Impacts Treatment Decision Making in Patients With Prostate Cancer Referred for Radiotherapy 46
Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate 46
Joint Practice Guidelines for Radionuclide Lymphoscintigraphy for Sentinel Node Localization in Oral/Oropharyngeal Squamous Cell Carcinoma 46
PET in radiotherapy planning: Particularly exquisite test or pending and experimental tool? 45
Totale 5.479
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.279
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.279
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 0 0 0 0 0 0 0 0 0 0 0 20
2020/20213.889 38 50 45 17 37 1.227 544 278 734 501 38 380
2021/20221.919 161 17 62 414 37 28 73 260 161 129 486 91
2022/20235.106 748 197 462 560 456 462 10 410 947 432 344 78
2023/20242.627 220 320 583 174 63 301 150 129 51 35 240 361
2024/202573 73 0 0 0 0 0 0 0 0 0 0 0
Totale 13.634